Fullerton Fund Management CO Ltd. Hutchmed (China) LTD Transaction History

Fullerton Fund Management CO Ltd.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$25.8 - $34.61 $182,380 - $244,658	-7,069 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$17.65 - $28.05 $11,825 - $18,793	670 Added 10.47%	7,069 $195,000
Q1 2020 May 15, 2020	SELL	$15.19 - $29.51 $71,165 - $138,254	-4,685 Reduced 42.27%	6,399 $114,000
Q4 2019 Feb 14, 2020	SELL	$17.17 - $25.95 $8,894 - $13,442	-518 Reduced 4.46%	11,084 $278,000
Q3 2019 Nov 14, 2019	BUY	$17.84 - $22.69 $48,346 - $61,489	2,710 Added 30.48%	11,602 $207,000
Q2 2019 Aug 14, 2019	SELL	$22.0 - $31.78 $23,078 - $33,337	-1,049 Reduced 10.55%	8,892 $196,000
Q4 2018 Feb 14, 2019	BUY	$23.09 - $37.69 $229,537 - $374,676	9,941 New	9,941 $230,000

8.25M

3.8K

2.4K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $3.11B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of Fullerton Fund Management CO Ltd., based on Form 13F filings with the SEC.

Stay updated on Fullerton Fund Management CO Ltd. with notifications on news.